Richard Vinitha, Lee Kevin, Kerin Michael Joseph
Discipline of Surgery, Lambe Institute for Translational Research, University of Galway, H91 V4AY Galway, Ireland.
School of Medicine, University of Galway, H91 V4AY Galway, Ireland.
Int J Mol Sci. 2025 Apr 7;26(7):3449. doi: 10.3390/ijms26073449.
Breast cancer is an aggressive disease of multiple subtypes with varying phenotypic, hormonal, and clinicopathological features, offering enhanced resistance to conventional therapeutic regimens. There is an unmet need for reliable molecular biomarkers capable of detecting the malignant transformation from the early stages of the disease to enhance diagnosis and treatment outcomes. A subset of small non-coding nucleic acid molecules, micro ribonucleic acids (microRNAs/miRNAs), have emerged as promising biomarkers due to their role in gene regulation and cancer pathogenesis. This review discusses, in detail, the different origins and hormone-like regulatory functionalities of miRNAs localized in tumor tissue and in the circulation, as well as their inherent stability and turnover that determines the utility of miRNAs as biomarkers for disease detection, monitoring, prognosis, and therapeutic targets.
乳腺癌是一种具有多种亚型的侵袭性疾病,具有不同的表型、激素和临床病理特征,对传统治疗方案的耐药性增强。目前迫切需要可靠的分子生物标志物,能够在疾病早期检测到恶性转化,以提高诊断和治疗效果。一小部分小的非编码核酸分子,即微小核糖核酸(microRNAs/miRNAs),因其在基因调控和癌症发病机制中的作用,已成为有前景的生物标志物。本综述详细讨论了位于肿瘤组织和循环中的miRNA的不同来源和类似激素的调节功能,以及它们固有的稳定性和周转情况,这些决定了miRNA作为疾病检测、监测、预后和治疗靶点生物标志物的效用。